Nucleome Therapeutics announces a strategic collaboration with Johnson & Johnson to map genetic associations linked to autoimmune disease

Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomics to discover precision medicines for complex diseases, announces today it has entered a research collaboration with Johnson & Johnson*.

Nucleome will use its proprietary machine learning and high-resolution 3D genomics technologies to unambiguously define the specific DNA changes that make patients more susceptible to certain autoimmune diseases and identify the pathological mechanisms underlying those diseases.

Using Nucleome’s technology, and in combination with Johnson & Johnson’s immunology and data sciences capabilities, the collaboration aims to discover new target genes and the cell types that drive autoimmune disease. Ultimately this information could facilitate the classification of patients most likely to respond to therapy.

Dr Stephen Harrison, CSO of the Nucleome, said:

We are delighted to be working with J&J to identify new targets and develop strategies for patient stratification in autoimmune disease. Nucleome’s unique technology will be used to identify how genetic differences affect gene function and how this drives disease, specifically by defining the relevant genes and cell types.

Facilitated by Johnson & Johnson Innovation

Notes to Editors
Nucleome was founded in 2019. The precision of its 3D genomics technology has the potential to improve drug discovery success rates both by discovering genetically-validated medicines, and by more accurately identifying patients who are likely to benefit from treatments. Nucleome’s platform can be applied to multiple disease indications and cell types, with an initial focus on inflammatory conditions.  In addition to building its own pipeline, the company is forging external collaborations in target discovery, target validation, and patient stratification.

Nucleome was founded by leading experts in gene regulation from the University of Oxford. The Company is backed by a world-class syndicate of investors that includes M Ventures, the strategic corporate venture capital arm of Merck KGaA; Johnson and Johnson Innovation-JJDC, Inc. (“JJDC”), the strategic venture capital arm of Johnson & Johnson; Pfizer Ventures, the venture group of Pfizer; British Patient Capital; and founding investor Oxford Science Enterprises.

Visit Nucleome Therapeutics